# Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

> **NCT04400591** · — · AVAILABLE · sponsor: **Juno Therapeutics, a Subsidiary of Celgene**

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse

## Interventions

- **BIOLOGICAL:** Nonconforming Lisocabtagene Maraleucel

## Key facts

- **NCT ID:** NCT04400591
- **Lead sponsor:** Juno Therapeutics, a Subsidiary of Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04400591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04400591, "Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04400591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*